Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy

Inhibitory antibodies to factor VIII (FVIII) are a major complication in the treatment of hemophilia A, affecting approximately 20% to 30% of patients. Current treatment for inhibitors is based on long-term, daily injections of large amounts of FVIII protein. Liver-directed gene therapy has been use...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Finn, Jonathan D., Ozelo, Margareth C., Sabatino, Denise E., Franck, Helen W. G., Merricks, Elizabeth P., Crudele, Julie M., Zhou, Shangzhen, Kazazian, Haig H., Lillicrap, David, Nichols, Timothy C., Arruda, Valder R.
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Hematology 2010
Ämnen:
Gene Therapy
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3031380/
https://ncbi.nlm.nih.gov/pubmed/20876851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-06-288001
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk